top of page

Cancer52 releases an analysis on rare and less common cancer research spend

In 2022, Cancer52 and the National Cancer Research Institute (NCRI) joined forces to create a report titled: Research into rare and less common cancers: An analysis of research spend by Cancer52 members and NCRI partners.


The report is in a digital format and can be accessed online. It provides a snapshot of non-industry research spend on rare and less common cancers, separate to the spend on the four most common cancers, lung, breast, bowel and prostate.



Top ten rare and less common cancers by mortality compared to research spend


The report looks at patterns in regional spend within the UK, as well as at the effect of the COVID-19 pandemic during the financial year 2020-2021.


Combined spend (Cancer52 members and NCRI Partners) by region




As you may have seen, the NCRI have recently announced its decision to wind down the organisation but have approved its release as the wind down does not affect the validity of the report.

Commentaires


bottom of page